Studies Show Biological Age Reduction with Eli Lilly and Novo Nordisk Drugs
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Studies involving Eli Lilly and Company and Novo Nordisk reported that their drugs reduced biological age by roughly two to three years in aging-clock assessments. Researchers cautioned that the drugs have side effects, and their effect on healthy people remains unknown.
From newsroomamerica.com
Why it matters
The clinical success reported validates the core value proposition of both companies' drugs. These findings support the companies' pivot toward longevity therapeutics, which increases competitive pressure within the pharmaceutical market.
Eli Lilly and Novo Nordisk have been shifting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.
From newsroomamerica.com
Who's involved
- Eli Lilly and CompanyAmerican pharmaceutical company involved in the biological age studies
- Novo NordiskDanish pharmaceutical company involved in the biological age studies
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Eli Lilly and CompanySpeculative
Could see revenue increase as the clinical success validates the core value proposition of its drugs.
- Novo NordiskSpeculative
Could see demand for its drugs increase following the reported clinical success.
- AbbVieSpeculative
Might face increased competitive pressure, potentially affecting market share and costs.
- Morgan StanleySpeculative
May see changes in investment research or market price coverage based on the new scientific data.
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company